source
- Alphabet’s GV tops biotech corporate investors with $5.23 billion in deals since 2025Alphabet’s venture arm GV has become the largest corporate spender in biotech, investing a cumulative $5.23 billion across 20 deals since the start of 2025. The total outlay exceeds the combined v…
- U.S. judge denies effort to block Eli Lilly's weight-loss ad; GSK reports oncology drug approvalA U.S. district judge rejected a request to halt Eli Lilly's advertising campaign that Novo Nordisk alleges is deceptive in promoting its weight‑loss medicines. Novo Nordisk argued the ads could m…